HER2-positive breast cancer accounts for about 20% of all breast cancer cases – SPCC
SPCC (Sharing Progress in Cancer Care) reshared a post by Definitive Trial on LinkedIn, adding:
“HER2-positive breast cancer accounts for about 20% of all breast cancer cases.
Identifying HER2 status is crucial for effective treatment. But it’s not that simple. HER2 intratumor heterogeneity affects treatment.
Read more.”
Quoting Definitive Trial‘s post:
“On World Cancer Day, we want to share with you the latest blog post on the Definitive Study website: Impact Of HER2-Positive Breast Cancer Heterogeneity On Treatment Selection.
HER2-positive breast cancer accounts for about 20% of all breast cancer cases.
Identifying HER2 status is crucial for effective treatment. But it’s not that simple… HER2 intratumor heterogeneity affects treatment.
Discover more in the carousel and read the complete info in our latest blog!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023